Immunoassay for Neurological Biomarkers Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Instruments, Reagents, Services), By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others), By Application (In Vitro Diagnostics, Research), By Region and Competition, 2020-2030F

November 2025 | 185 pages | ID: IFFE32263455EN
TechSci Research

Abstracts

The Global Immunoassay for Neurological Biomarkers Market, valued at USD 654.22 Million in 2024, is projected to experience a CAGR of 11.65% to reach USD 1267.29 Million by 2030. Immunoassays for neurological biomarkers encompass protein-based tests designed to detect and quantify specific molecular interactions indicative of neurological disorders within biological samples. The global market for these diagnostics is primarily driven by the escalating prevalence of neurodegenerative conditions and the increasing demand for early and precise diagnostic tools.

Key Market Drivers

The increasing prevalence of neurological disorders globally constitutes a primary impetus for the immunoassay market for neurological biomarkers. The increasing longevity of the global population, coupled with environmental and lifestyle factors, contributes to a rising burden of neurodegenerative conditions. For instance, according to a study published in The Lancet in March 2024, the Global Burden of Disease, Injuries, and Risk Factors study 2021 revealed that 3.4 billion people, representing 43% of the world's population, were affected by neurological conditions in 2021. This widespread occurrence underscores an urgent clinical need for accurate and accessible diagnostic and monitoring tools, driving demand for advanced biomarker detection and effective therapeutic intervention development.

Key Market Challenges

The market for immunoassays in neurological biomarkers faces significant impedance due to stringent regulatory hurdles and the inherent complexity of standardizing biomarker panels. These obstacles directly constrain the introduction of novel assays and complicate their widespread clinical adoption. For instance, according to MedTech Europe's 2024 survey results, which includes data up to October 2023, certification and maintenance costs for in vitro diagnostic (IVD) devices under the new European IVD Regulation (IVDR) have escalated by 100% or more compared to previous directives, diverting substantial personnel and financial resources away from innovation and market expansion. This increase in regulatory burden and cost creates unpredictable timelines for manufacturers, particularly impacting smaller and medium-sized enterprises.

Key Market Trends

The integration of Artificial Intelligence for enhanced biomarker detection and analysis significantly impacts the immunoassay market for neurological biomarkers. AI algorithms process complex multimodal data, including imaging and clinical records, identifying subtle biomarker patterns crucial for diagnosing neurological disorders. This capability enables precise disease stratification and personalized therapeutic approaches. According to AdvaMed, in 2022, at least 91 new algorithms gained FDA approval in the first ten months, impacting diagnostic markets. Illustrating this, the University of Liverpool announced in October 2025 the development of a low-cost, handheld AI-powered blood test for early Alzheimer's detection. This innovation highlights AI's role in advancing accurate diagnostic tools.

Key Market Players

• QIAGEN NV
• Abbott Laboratories Inc.
• Merck & Co., Inc.
• Johnson & Johnson Services, Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Sysmex Corporation
• F. Hoffmann La-Roche Ltd.
• Nimble Therapeutics Inc.
• HD Biosciences Co., Ltd.

Report Scope:

In this report, the Global Immunoassay for Neurological Biomarkers Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Immunoassay for Neurological Biomarkers Market, By Product:
• Instruments
• Reagents
• Services
• Immunoassay for Neurological Biomarkers Market, ¬By Disease:
• Alzheimer's Disease
• Parkinson's Disease
• Multiple Sclerosis
• Others
• Immunoassay for Neurological Biomarkers Market, By Application:
• In Vitro Diagnostics
• Research
• Immunoassay for Neurological Biomarkers Market, By Region:
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Immunoassay for Neurological Biomarkers Market.

Available Customizations:

Global Immunoassay for Neurological Biomarkers Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Product (Instruments, Reagents, Services)
  5.2.2. ¬By Disease (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Others)
  5.2.3. By Application (In Vitro Diagnostics, Research)
  5.2.4. By Region
  5.2.5. By Company (2024)
5.3. Market Map

6. NORTH AMERICA IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Product
  6.2.2. ¬By Disease
  6.2.3. By Application
  6.2.4. By Country
6.3. North America: Country Analysis
  6.3.1. United States Immunoassay for Neurological Biomarkers Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Product
      6.3.1.2.2. ¬By Disease
      6.3.1.2.3. By Application
  6.3.2. Canada Immunoassay for Neurological Biomarkers Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Product
      6.3.2.2.2. ¬By Disease
      6.3.2.2.3. By Application
  6.3.3. Mexico Immunoassay for Neurological Biomarkers Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Product
      6.3.3.2.2. ¬By Disease
      6.3.3.2.3. By Application

7. EUROPE IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Product
  7.2.2. ¬By Disease
  7.2.3. By Application
  7.2.4. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Immunoassay for Neurological Biomarkers Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Product
      7.3.1.2.2. ¬By Disease
      7.3.1.2.3. By Application
  7.3.2. France Immunoassay for Neurological Biomarkers Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Product
      7.3.2.2.2. ¬By Disease
      7.3.2.2.3. By Application
  7.3.3. United Kingdom Immunoassay for Neurological Biomarkers Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Product
      7.3.3.2.2. ¬By Disease
      7.3.3.2.3. By Application
  7.3.4. Italy Immunoassay for Neurological Biomarkers Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Product
      7.3.4.2.2. ¬By Disease
      7.3.4.2.3. By Application
  7.3.5. Spain Immunoassay for Neurological Biomarkers Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Product
      7.3.5.2.2. ¬By Disease
      7.3.5.2.3. By Application

8. ASIA PACIFIC IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Product
  8.2.2. ¬By Disease
  8.2.3. By Application
  8.2.4. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Immunoassay for Neurological Biomarkers Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Product
      8.3.1.2.2. ¬By Disease
      8.3.1.2.3. By Application
  8.3.2. India Immunoassay for Neurological Biomarkers Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Product
      8.3.2.2.2. ¬By Disease
      8.3.2.2.3. By Application
  8.3.3. Japan Immunoassay for Neurological Biomarkers Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Product
      8.3.3.2.2. ¬By Disease
      8.3.3.2.3. By Application
  8.3.4. South Korea Immunoassay for Neurological Biomarkers Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Product
      8.3.4.2.2. ¬By Disease
      8.3.4.2.3. By Application
  8.3.5. Australia Immunoassay for Neurological Biomarkers Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Product
      8.3.5.2.2. ¬By Disease
      8.3.5.2.3. By Application

9. MIDDLE EAST & AFRICA IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Product
  9.2.2. ¬By Disease
  9.2.3. By Application
  9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Immunoassay for Neurological Biomarkers Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Product
      9.3.1.2.2. ¬By Disease
      9.3.1.2.3. By Application
  9.3.2. UAE Immunoassay for Neurological Biomarkers Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Product
      9.3.2.2.2. ¬By Disease
      9.3.2.2.3. By Application
  9.3.3. South Africa Immunoassay for Neurological Biomarkers Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Product
      9.3.3.2.2. ¬By Disease
      9.3.3.2.3. By Application

10. SOUTH AMERICA IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Product
  10.2.2. ¬By Disease
  10.2.3. By Application
  10.2.4. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Immunoassay for Neurological Biomarkers Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Product
      10.3.1.2.2. ¬By Disease
      10.3.1.2.3. By Application
  10.3.2. Colombia Immunoassay for Neurological Biomarkers Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Product
      10.3.2.2.2. ¬By Disease
      10.3.2.2.3. By Application
  10.3.3. Argentina Immunoassay for Neurological Biomarkers Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Product
      10.3.3.2.2. ¬By Disease
      10.3.3.2.3. By Application

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL IMMUNOASSAY FOR NEUROLOGICAL BIOMARKERS MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. QIAGEN NV
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Abbott Laboratories Inc.
15.3. Merck & Co., Inc.
15.4. Johnson & Johnson Services, Inc.
15.5. Thermo Fisher Scientific, Inc.
15.6. Bio-Rad Laboratories, Inc.
15.7. Sysmex Corporation
15.8. F. Hoffmann La-Roche Ltd.
15.9. Nimble Therapeutics Inc.
15.10. HD Biosciences Co., Ltd.

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER